The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcomes of beta blockers (BB) in hepatocellular carcinoma (HCC) treated with immune checkpoint inhibitors (ICIs).
 
Linda Wu
No Relationships to Disclose
 
Umut Ozbek
No Relationships to Disclose
 
Grace van Hyfte
No Relationships to Disclose
 
Marlene Reincke
No Relationships to Disclose
 
Anuhya Gampa
No Relationships to Disclose
 
Yehia I. Abugabal
No Relationships to Disclose
 
Naoshi Nishida
No Relationships to Disclose
 
Brooke Wietharn
No Relationships to Disclose
 
Suneetha Amara
No Relationships to Disclose
 
Lorenz Balcar
No Relationships to Disclose
 
Matthias Pinter
No Relationships to Disclose
 
Arndt Vogel
Honoraria - Amgen; Bristol-Myers Squibb; Ipsen; Janssen; Lilly; MSD; Novartis; Pierre Fabre; Roche; Sanofi
Consulting or Advisory Role - Amgen; AstraZeneca; Baxalta; Bayer; BTG; Eisai; IPSEN; Lilly; Novartis; Pierre Fabre; Roche
Research Funding - Novartis
Travel, Accommodations, Expenses - Bayer; Ipsen; Roche
 
Arndt Weinmann
No Relationships to Disclose
 
Anwaar Saeed
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Exelixis; Five Prime Therapeutics; Pfizer
Speakers' Bureau - Daiichi Sankyo/Astra Zeneca
Research Funding - Actuate Therapeutics (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Daiichi Sankyo/UCB Japan (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); KAHR Medical (Inst); Merck Sharp & Dohme (Inst); Seagen (Inst)
 
Lorenza Rimassa
No Relationships to Disclose
 
Abdul Rafeh Naqash
No Relationships to Disclose
 
Mahvish Muzaffar
No Relationships to Disclose
 
Yi-Hsiang Huang
No Relationships to Disclose
 
David James Pinato
Honoraria - Bristol-Myers Squibb; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Da Volterra; Eisai; H3 Biomedicine; Mina Therapeutics; Roche
Speakers' Bureau - Bayer; Falk Pharma; Roche; ViiV Healthcare
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline (Inst); MSD Oncology
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; MSD Oncology
 
Celina Ang
No Relationships to Disclose